. Author manuscript; available in PMC: 2007 Dec 21.

Published in final edited form as: Clin Cancer Res. 2006 Apr 15;12(8):2526–2537. doi: 10.1158/1078-0432.CCR-05-2061

Table 2.

Clinical response evaluation of patients on the randomized trial

	No. patients (response duration in months)^*
	Arm 1	Arm 2	Arm 3	Arm 4^†
Randomized	13	14	20	NA
Evaluable	13	13	19	17
CR	0	0	0	0
PR	0	0	2 (4, 8)	5 (3, 4, 9,18, 40+)
MR	0	0	0	0
MXR	1	2	6	3
SD	1 (6)	1 (4)	1 (4)	1 (5)
PD	11	10	10	8

Abbreviations: NA, not applicable; CR, complete response; PR, partial response; MR, minor response; MXR, mixed response; SD, stable disease; PD, progressive disease.

Duration of stable disease was measured from initiation of treatment. Duration of response was measured from date of achieving response.

^†

In nonrandomized Arm 4, select patients from Arms 1 and 2 with progressive disease subsequently received high-dose IL-2 as single-agent therapy.